bloodstream, 85% of thiopental is bound to plasma proteins, mainly albumin, and only the free unbound drug is available for pharmacological effect. Compared with adults, the requirement for thiopental is reduced in neonates (due to decreased plasma protein binding, longer half-time elimination, greater penetration into the neonatal brain), but is increased in infants and children for the increased cardiac output which should reduce the fistpass concentration of the drug arriving to the brain. This drug can be irritating if not injected intravenously, since crystals can be formed within the arterioles and capillary lumen, causing vasoconstriction, thrombosis and even tissue necrosis.
Thiopental is commonly used for the induction-phase of anesthesia, but it is seldom used for maintenance because of the long half-time (about II hours) and prolonged recovery period. Thiopenthal improves cerebral perfusion and decreases both cerebral oxygen metabolic rate and intracranial pressure. These actions are considered "neuroprotective" , therefore this drug is often used during neurosurgery. Thiopenthal is a potent anticonvulsant, and continuous infusions have been used to control refractory status epilepticus. Important cardiovascular effects are hypotension (secondary to myocardial depression and vasodilatation) and tachycardia.
Thiopental has a dose-related depressant effect on both respiratory rate and depth, and depresses the sensitivity of the respiratory centre to carbon dioxide. A short period of apnea is common after an induction dose. The loss of airway reflexes contraindicates its use in patients with airway obstruction. Furthermore, laryngospasm and bronchospasm may occur if upper airway manipulation is performed.
A meticulous care of airway and cardiovascular parameters is essential during induction ofanesthesia with thiopental. A transient urticarial response in perioperative period is not uncommon, caused by histamine release activity of the drug. Anaphylactic response are rare events, but are associated with a high mortality.
Propofol
Propofol (2-6 diisopropylphenol) is a chemically inert phenolic compound. Commercial preparations contain propofol in an oil-water emulsion, containing 10% or 20% soybean oil, 2% glycerol, and I% egg phosphatide.
Propofol is a central acting sedative agent and does not have analgesic properties. The induction dose produces rapid loss of consciousness as a result of the immediate uptake of the lipid soluble drug into the brain. After the distribution, recovery offull consciousness is rapid. Doses of propofol are higher in children than in adults for the larger volume of the central compartment and the faster plasma clearance. In CNS, the drug decreases cerebral metabolism and intracranial and intraocular pressure.
Propofol has some undesiderable properties. Excitatory neurological side effects (e.g. myoclonus, opisthotonus, convulsions) are reported. Pain on injection is frequent and can be minimized by a slow injection into a large vein or by a co-administration of lidocaine (3) . Propofol causes hypotension (by direct vaso-and veno-dilatation), suppression of the vasomotor centre and alteration of the baroreceptor reflex. There are case reports of propofolinduced myocardial depression with severe bradycardia. To avoid these effects, lower induction and maintenance doses are recommended (3) .
Propofol is a potent respiratory depressant and generally produces apnea after an induction dose. A maintenance infusion will reduce minute ventilation through a reduction of tidal volume and respiratory rate. In addition, the ventilatory response to hypoxia and hypercapnia is reduced. The drug causes reduction in upper airway reflexes (which makes it well suited for instrumentation of the airway) and decreases the incidence of wheezing during the perioperative period in asthmatic patients.
Several cases of anaphylaxis to propofol have been described. A risk of cross-allergic reactions between peanut and soy bean oil contained in propofol formulation, and between lecithin -a purified egg phospholipid present in the lipid vehicle of propofol -and other proteins in white egg (ovoalbumin, ovomucoid, conalbumin) has been postulated. Allergic reactions to propofol have been shown to be frequently triggered by the iso-propyl or phenol groups rather than the lipid vehicle (4).
The use of propofol for prolonged sedation in pediatric intensive care units has been associated with a rare syndrome (PRopofol Infusion Syndrome: PRIS), originally described in critically ill children undergoing propofol infusion but recently, described also in adults. All cases of PRIS have the following features in common: large dose of propofol, prolonged duration of infusion, severe metabolic acidosis, ventricular failure, hemodynamic instability, lipemic plasma, enlarged liveror fatty liver at autopsy, muscle involvement with evidence of rhabdomyolysis or myoglobinuria, multiorgan failure and death. Impaired fatty acid oxydation and dysfunction of mitochondrial respiration might explain clinical and biochemical findings. PRIS Propofol infusion syndrome seems to mimic mitochondrial myopathies, in which there are specific defects in the mitochondrial respiratory chain (5) .
Opioids
Opioids are peptides, natural or synthetic, that interact with opioid receptors, whose stimulation activates the GABAergic system. Three well defined classes of opioid receptors (u, 0, K,) and three subtypes of Il receptors have been described (lll,2,3). Most opioids used in clinical anesthesia are highly selective for III and 112 (6) .
Opioids remain the most powerful and widely used group of analgesics. They can be administered by many routes and are considered safe, provide accurate dosing regimens and appropriate monitoring and staff education. In neonates and early infancy, the clearance and protein binding of opioids are reduced and the halflife is increased. These features, which are dependent on gestational age and birth weight, are mainly due to reduced metabolism and immature renal function.
All opioids produce a dose-related depression of ventilation. The primary effect is a reduction in the sensitivity of the respiratory centre to C02, but they also depress the medullar and peripheral chemoreceptors. Initially, respiratory rate is affected more than tidal volume, but with increasing doses respiratory rhythm results in the irregular, grasping breathing of opioid overdose. Muscle rigidity involving the thoracic and abdominal muscles can sometime interfere with ventilation. Opioids can also produce smooth muscle spasm throughout the gastrointestinal tract and increase the tone of the common bile duct and sphincter of Oddi. With low doses opioids, they have minimal cardiovascular effects, but bradycardia and hypotension are seen with higher doses. All opioids can produce nausea and vomiting through interactions with specific centers in the medulla.
Morphine is the most widely studied and used opioid in children. It can be given through an oral, subcutaneous, intramuscular, intravenous, epidural, intraspinal, and rectal route. Morphine is indicated for analgesia due to reliable and predictable effects, safety profile and easy reversibility with naloxone. It possess some sedative effects, but has no amnestic properties. It sometimes produces dysphoria and an unpleasant sensation of fear and anxiety. Frequent side effects of morphine are emesis, miosis and depression of the cough reflex.
Fentanyl is a more potent opioid than morphine, with a rapid onset and short duration of action. It has less cardiovascular effects and is safer in patients with hyperreactive airway disease than morphine, because of its minimal histamine release properties. Due to high lipophilicity, fentanyl can also be delivered via the transdermal or transmucosal route. There are differences in pharmacokinetics between bolus doses and prolonged infusion with highly lipophilic drugs, such as fentanyl; the context sensitive half-time progressively increases with the duration of infusion.
Remifentanyl is a synthetic opioid used for analgesia during induction and/or maintenance of general anesthesia. It has also been used to provide analgesia in the immediate postoperative period. Hydrolysis occurs by blood and tissue esterases; plasma cholinesterase deficiency has little effect on metabolism ofremifentanyI. Remifentanyl is given intravenously, usually by infusion and provides rapid onset and rapid offset of action. Remifantanyl is a strong respiratory depressant: it can be used in the spontaneously breathing patient as a low-dose infusion, but the child must be nursed in an appropriate area with adequate monitoring. When appropriate, alternative analgesics should be given before stopping remifentanyl, in sufficient time to provide continuous and more prolonged pain relief (7) .
Benzodiazepines
Benzodiazepines are psychoactive drugs whose core chemical structure is the fusion of a benzene and a diazepine ring. The three commonly used benzodiazepines in the perioperative setting include diazepam, lorazepam and midazolam, as well as the selective benzodiazepine antagonist f1umazenyI. They are all highly lipophylic, with midazolam having the highest lipid solubility. They are classified as either short (midazolam), intermediate (diazepam) or long-acting (Iorazepam). Although they can be used as hypnotics, benzodiazepines are primarily used as premedicants and adjuvant drugs.
The most important effects of benzodiazepines are their sedative-hypnotic action and their amnestic properties (anterograde amnesia). In addition, they are anticonvulsants, anxiolytic and muscle relaxant drugs. Sedative-hypnotic action is mediated by stimulation of alfa-I subunits of the GABA receptor, whereas anxiolysis and muscle relaxation are mediated through the interaction with gamma subunits.
The most significant adverse effect ofbenzodiazepines are respiratory depression and subsequent hypoxemia, therefore caution occurs when administering this medication to patients with underlying asthma or other obstructive respiratory diseases. Cardiovascular depression, resulting in hypotension with reflex tachycardia, is another adverse effect.
Midazolam is the most commonly used benzodiazepine in pediatric anesthesia, because ofits prompt onset ofaction and short half-life. Diazepam may also be given, but has a long half-life and produces active metabolites. Lorazepam is a poor choice for procedural sedation because of its long duration of action. Midazolam produces minimal venous irritation as opposed to diazepam and lorazepam, which are formulated in propylene-glycol and are painful on injection.
Ketamine
Ketamine is a phencyclidine derivative water soluble compound, available in 1%, 5% and 10% solutions. It is metabolized through the oxydase system in the liver (its main metabolite, norketamine, has a minor hypnotic activity and a longer elimination half-time) and eliminated by the kidney. Ketamine can be administered by multiple routes (intravenous, intramuscular, oral, rectal, epidural), thus making it a useful option for premedication in uncooperative pediatric patients. In emergency situations, it can be given satisfactorily by intraosseus route (8) .
Ketamine is water soluble and lipophilic. It is an ideal induction agent because it produces rapid sedation, has brief duration of action and possess both analgesic and amnestic properties. This drug produces a slow loss of consciousness and a state of dissociative anesthesia: the eyes may remain open with a fixed gaze, the eyelash and corneal reflexes remain unimpaired, and there is usually increased muscle tone with some involuntary movements.
Emergence delirium with restlessness, disorientation and unpleasant dreams or hallucinations may occur for up to 24 hours following ketamine administration. The incidence of these effects is reduced by concomitant administration of opioids, benzodiazepines or propofol. Ketamine is controindicated in patients with a history of psychotic illness and in the presence of increased intracranial or intraocular pressure. An important adverse effect is laryngospasm: although it is usually manageable with conservative techniques, expertise and equipment must be available to manage the airway in this situation.
Ketamine also inhibits catecholamine reuptake at the neuromuscular junction, which leads to slight increases in the heart rate, blood pressure and cardiac output. Owing to the increased cardiac work and myocardial consumption, ketamine adversely affects the balance between myocardial oxygen supply and demand. Consequently, it is not recommended for use in subjects with hypertension or cardiovascular diseases. On the other hand, ketamine may be ideal for patients with hypotension, such as those experiencing hemorrhagic, hypovolemic, or septic shock.
Ketamine is the induction agent of choice in patients with bronchospasm, because it is the only intravenous anesthetic with bronchodilatory properties. Although the bronchial smooth muscle relaxes, airway reflexes remain intact. When ketamine is used in patients with asthma who are dependent on ventilators, respiratory acidosis and airway pressures are decreased compared to control subjects (9) .
Neuromuscular blocking agents
Neuromuscular blocking agents (NMBA) are quaternary ammonium compounds that have at least one nitrogen atom that binds to the alta subunit of postsynaptic cholinergic receptor at the endplate of muscle. This action interrupts the transmission of nerve impulses and thereby produces paresis or paralysis of skeletal muscle. NMBA are used to improve conditions for tracheal intubation, to provide immobility during surgery and to facilitate mechanical ventilation. Important characteristics of muscle relaxants include potency, onset time, maintenance requirement and reversibility of their neuromuscular effects: all these characteristics are agedependent (10) . On the basis of their modes of action, NMBA can be classified into two types: depolarizing and non-depolarizing agents.
Depolarizing NMBA
These drugs mimic the action of acethylcholine and produce depolarization at the endplate. Succinylcholine is the only depolarizing muscle relaxant for clinical use. Elimination of succinylcholine depends on hydrolysis by cholinesterase, hence a deficiency in this enzyme may result in prolonged block. Important side effects are postoperative muscle pain, increased intraocular pressure, malignant hyperpyrexia, bradycardia, hyperkalemia, masseter muscle spasm. In spite of these undesiderable effects, succinylcholine is still used because it is the only ultra-rapid onset/ultra-short duration NMBA currently available. Additionally, succinylcholine is the only NMBA which is effective by intramuscular route and thus particularly useful in children with difficult intravenous access.
Nondepolarizing NMBA
These drugs act by competing with acetylcholine for alfa subunits at the post-junctional cholinergic receptors. Structurally, they are either aminosteroids (e.g. vecuronium, rocuronium) or benzyquinoliniums (e.g, atracurium, cisatracurium, mivacurium). They can also be classified according to their duration of action, as shortacting (effect up to 15 min: mivacurium), medium-acting (effect up to 40 min: atracurium, vecuronium, rocuronium) and long-acting (effect up to 60 min: pancuronium).
The reduced half-times of these drugs in infants and children correlates with reduced duration of action. It is thought to result from its distribution into a larger volume of extracellular fluid rather than an altered response to the action of the drug at post-junctional acetylcholine receptors. Consequently, pediatric dosages vary with age. In newborns, muscular hypotonia is physiologic and the use of muscle relaxants is not suitable (II ).
-Atracurium undergoes spontaneous degradation at body pH and temperature. Consequently, it does not have cumulative effects and there is no need to adjust dosage in pediatric patients when compared with adults. Adverse effects of atracurium are mainly related to accumulation of one major metabolite, laudanosine, that may produce excitatory CNS toxicity, even seizures. Rapid intravenous administration may produce transient increase in heart 101.J. ImmuoopalhoI. Pharmacol. rate and hypotension. Atracurium is an histamine releasing drug and can cause urticaria or cutaneous rashes after administration.
-Cisatracurium has a similar pharmacokinetic profile to atracurium, but the potency is higher and the onset time is longer. Cisatracurium has the same side effects of atracurium, but manifestations of histamine release are rare in clinical practice (12) .
-Mivacurium is hydrolyzed by plasma cholinestherase, like succinylcholine. The drug is presented as a mixture of three isomers; the cis-trans and trans-trans have short half-lives, but the cis-cis isomer (that accounts for only 6% of the mixture) has a long half-life. Plasma clearance of mivacurium decreases with age. In children, onset of block and recovery are more rapid than in adults and infusion rate required to maintain blockade is greater. Furthermore, cardiovascular effects, such as hypotension and tachycardia, are not as important as in adults. Mivacurium has significant histamine releasing properties that may be evident at therapeutic doses. These effects are frequently short-lived and anaphylaxis is a rare event (13) .
-Rocuronium has rapid onset and intermediate duration of action, that makes this agent a potential replacement for succinylcholine in emergence surgery. Cardiovascular effects consist in a small increase in heart rate and a reduction in blood pressure. Pulmonary side-effects, such bronchospasm, are more common in patients with bronchial hyperreactivity and/or undergoing a rapid sequence induction of anesthesia and appear to be dose-related. These are frequently severe in infants and children, albeit short-lived and self-limiting (14) .
INHALED ANESTHETICS
Inhaled anesthetics are gases rapidly transferred bidirectionally via the lungs to and from the bloodstream and subsequently to and from CNS. Major advantages of inhalational anesthetics are rapid induction of anesthesia, easy maintenance of proper depth of anesthesia, easy monitoring ofanesthetic concentration and rapid recovery. With the exception of nitrous oxide (N20), all the agents in current use are halogenated organic compounds (15) .
Potency of inhalational anesthetic agents is measured by minimum alveolar concentration (MAC) that produces immobility in 50% of subjects exposed to a noxious stimulus (surgical skin incision). The higher MAC in neonates and infants compared with older children and adults may be due to reduced solubility of inhaled anesthetics in brain tissue owing to a greater content of water. Uptake and elimination of inhaled anesthetics occur more rapidly in pediatric patients than in adults, due to increased levels of ventilation in relation to functional residual capacity, increased cardiac output and reduced solubility of the inhaled anesthetics in the blood. The most used inhaled anesthetics in surgical procedures are isoflurane, desflurane, sevoflurane, -Isoflurane is an halogenated methyl-ethyl-ether. It is the most potent of the volatile anesthetics in clinical use, has a great physical stability and produces a rapid induction of anesthesia. It is the agent of choice in neurosurgery, as it minimally affects intracranial pressure. The drug can cause depression of myocardial contractility, tachycardia, vasodilatation and hypotension. Whereas it preserves the cardiac output, isoflurane produces coronary vasodilatation and does not increase the incidence of arrhytmia.
Isoflurane is considered an agent of choice in cardiac patients, but its use is controversial in patients with coronary diseases, because of the possibility of coronary "steal" phenomenon caused by high concentrations of the drug. It may cause reduction of minute ventilation and respiratory depression, that can be partially offset by surgical stimulus. In the absence of stimulus, apnea usually occurs. Isoflurane has bronchodilator effects, but its pungent odor may cause airway irritation, bronchospasm or laryngospasm (16) .
-Desflurane is a fluorinated ether, structurally related to isoflurane. It tends to boil at room temperature; heated and pressurized vaporizer is required to deliver it. When compared with isoflurane, fluorination of desflurane results in a low tissue and blood solubility, greater stability and loss of potency. The onset of anesthesia and recovery are rapid. Desflurane is unique among volatile agents in stimulating sympathetic system, and in selected cases, when used in high concentrations, myocardial depression and ischemia may occur. Desflurane can also cause respiratory depression. Airway irritation limits the use of desflurane for inhalational induction; it can cause respiratory irritation, with high incidence ofbreath holding and laryngospasm. The rapid recovery characteristics make it a suitable drug for use in ambulatory anaesthesia.
-Sevoflurane is a fluorinated methyl-isopropyl ether. Compared with isoflurane, sevoflurane is less soluble in blood and tissues, and is less potent. Cardiovascular stability is well preserved and it lacks coronary artery vasodilating properties. Sevoflurane has minimal odor and is a potent bronchodilator. These attributes make it an excellent drug for induction ofanesthesia. It is the inhaled anesthetic most commonly used in pediatric patients.
LOCAL ANESTHETICS
Local anesthetics are a class of drugs that act by reversibly blocking sodium channels in nerves. Local anesthetic agents conform to a similar molecular configuration consisting of a lipophilic aromatic ring connected to a hydrophilic amine group. In solution, these drugs exist in ionized and non-ionized forms, the proportions ofwhich vary with the pH ofthe environment. Only the non-ionized portion is capable of diffusing across nerve membranes and blocking sodium channels. A decrease in pH shifts equilibrium towards the ionized form, delaying the onset of action. This explains why local anesthetics are slower in onset of action and less effective in the presence of inflammation, which creates a more acidic environment with lower pH (17, 18, 19) .
The many available local anesthetics can be categorized as either amino-esters (e.g. procaine, tetracaine, clorprocaine) or amino-amides (e.g. prilocaine, lidocaine, mepivacaine, bupivacaine, ropivacaine, levobupivacaine). Amino-esters and amino-amides differ in several aspects: metabolism (amino-esters are metabolized in the plasma via pseudo-cholinesterases, whereas amino-amides are metabolized in the liver), stability (amino-esters are unstable in solution, whereas amino-amides are stable) and allergenicity (amino-esters are much more likely than amino-amides to cause allergic reactions).
Amides are used most frequently in clinical practice. Commercial preparations ofIocal anesthetics are typically provided in formulations of 1% or 2% concentrations, available for topical application to mucosae or intact skin, for local installation or infiltration, for peripheral nerve or plexus blockade, for epidural injection or infusion, and for subarachnoid administration. Vasoconstrictors may be added to reduce the systemic absorption of local anesthetics and to prolong the neural blockade.
The two major binding proteins for local anesthetics in the blood are alfa-I-acid glycoprotein (AAG), the influence of which is predominant at low concentrations, and albumin, which plays the major role at high concentrations. Neonates and infants have low levels of AAG and this leads to higher serum levels of unbound local anesthetic responsible for toxicity. Suggested doses of the main local anesthetics are shown in Table 2 .
-Bupivacaine is an amide with a slow onset and a long duration of action (4-6 h). Standard bupivacaine is a racemic mixture of two isomers, R (+) and S (-). Both isomers have similar local anesthetic efficacy, but the Sisomer has a safer side effect profile. Dose ofbupivacaine in infants younger than 6 months of age should be halved, and considerations should be given to reducing the rate of infusion as there is evidence of drug accumulation even with these reduced doses. It is used mainly for infiltration anesthesia and regional nerve blocks, particularly epidural block, but is contraindicated for intravenous regional anesthesia because it may produce cardiac depression.
-Levobupivacaine is the S (-) enantiomer of bupivacaine with equipotence but less toxicity. It is available in the same concentrations as bupivacaine and is used for similar indications. Like bupivacaine, it is contraindicated for use in intravenous regional anesthesia (19) .
-Ropivacaine structurally differs from bupivacaine in that the butyl group attached to tertiary amine is replaced with a propyl group. It has an onset and duration of sensory block which is generally similar to that obtained with bupivacaine, but motor block may be slower in onset, shorter in duration and less intense. This drug has reduced toxicity compared to racemic bupivacaine (20) .
